STAT+: A biotech hedge fund births a new immunology company
Why a biotech hedge fund decided to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis.
<p>Why a biotech hedge fund decided to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis.</p>